Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tasurgratinib in Subjects With Hepatic Impairment
NCT04271488Phase 1Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasurgratinib (3 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration versus Time Curve from Time 0 to Time of Last Quantifiable Concentration and 1 more. Started Feb 2020; status: recruiting.
02
Drugs
tasurgratinib
Beyond the preview
Go deeper on NCT04271488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271488.